Μ-opioid receptor

OPRM1
Identifiers
Aliases	OPRM1, LMOR, M-OR-1, MOP, MOR, MOR1, OPRM, opioid receptor mu 1
External IDs	OMIM: 600018; MGI: 97441; HomoloGene: 37368; GeneCards: OPRM1; OMA:OPRM1 - orthologs
Gene location (Human)
Chr.	Chromosome 6 (human)
End	154,246,867 bp
Gene location (Mouse)
Chr.	Chromosome 10 (mouse)
End	6,988,198 bp
RNA expression pattern
	Top expressed in
	gonad; ; testicle; ; right hemisphere of cerebellum; ; sperm; ; left testis; ; right testis; ; prefrontal cortex; ; Brodmann area 9; ; nucleus accumbens; ; hypothalamus;
	Top expressed in
	medial habenular nucleus; ; autonomic nerve plexus; ; myenteric plexus; ; Subplate; ; spinal ganglia; ; embryo; ; nucleus of trigeminal nuclear complex; ; greater petrosal nerve; ; superior frontal gyrus; ; granulocyte;
	More reference expression data
	More reference expression data
Gene ontology
Molecular function	voltage-gated calcium channel activity; morphine receptor activity; G protein-coupled receptor activity; neuropeptide binding; signal transducer activity; filamin binding; G protein-coupled opioid receptor activity; protein binding; beta-endorphin receptor activity; G-protein alpha-subunit binding; protein C-terminus binding; protein domain specific binding; G-protein beta-subunit binding; peptide binding;
Cellular component	postsynapse; cytoplasm; integral component of membrane; perikaryon; Golgi apparatus; membrane; focal adhesion; integral component of plasma membrane; dendrite membrane; endoplasmic reticulum; neuron projection; membrane raft; sarcolemma; dendrite cytoplasm; plasma membrane; dendrite; endosome; axon; cell projection; spine apparatus; integral component of postsynaptic membrane; integral component of presynaptic membrane;
Biological process	positive regulation of appetite; negative regulation of adenylate cyclase activity; adenylate cyclase-activating dopamine receptor signaling pathway; sensory perception; negative regulation of cAMP-mediated signaling; adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; regulation of sensory perception of pain; eating behavior; locomotory behavior; estrous cycle; positive regulation of cytosolic calcium ion concentration; positive regulation of nitric oxide biosynthetic process; G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; negative regulation of Wnt protein secretion; wound healing; acute inflammatory response to antigenic stimulus; positive regulation of cAMP-mediated signaling; positive regulation of neurogenesis; regulation of NMDA receptor activity; phospholipase C-activating G protein-coupled receptor signaling pathway; response to morphine; response to lipopolysaccharide; negative regulation of nitric oxide biosynthetic process; calcium ion transmembrane transport; excitatory postsynaptic potential; positive regulation of ERK1 and ERK2 cascade; behavioral response to ethanol; response to food; sensory perception of pain; response to radiation; response to growth factor; response to ethanol; signal transduction; negative regulation of cell population proliferation; negative regulation of cytosolic calcium ion concentration; adenylate cyclase-inhibiting opioid receptor signaling pathway; response to cocaine; cellular response to morphine; chemical synaptic transmission; neuropeptide signaling pathway; G protein-coupled opioid receptor signaling pathway; G protein-coupled receptor signaling pathway; cytokine-mediated signaling pathway; regulation of cellular response to stress; negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway;
	Sources:Amigo / QuickGO
Orthologs
	4988
	18390
	ENSG00000112038
	ENSMUSG00000000766
	P35372
	P42866
NM_000914; NM_001008503; NM_001008504; NM_001008505; NM_001145279;
	NM_001145280; NM_001145281; NM_001145282; NM_001145283; NM_001145284; NM_001145285; NM_001145286; NM_001145287; NM_001285522; NM_001285523; NM_001285524; NM_001285526; NM_001285527; NM_001285528
NM_001039652; NM_011013; NM_001302793; NM_001302794; NM_001302795;
	NM_001302796; NM_001304937; NM_001304938; NM_001304948; NM_001304950; NM_001304955
NP_000905; NP_001008503; NP_001008504; NP_001008505; NP_001138751;
	NP_001138752; NP_001138753; NP_001138754; NP_001138755; NP_001138756; NP_001138757; NP_001138758; NP_001138759; NP_001272451; NP_001272452; NP_001272453; NP_001272455; NP_001272456; NP_001272457
NP_001034741; NP_001289722; NP_001289723; NP_001289724; NP_001289725;
	NP_001291866; NP_001291867; NP_001291877; NP_001291879; NP_001291884
	Wikidata
View/Edit Human	View/Edit Mouse

The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. They are also referred to as μ(mu)-opioid peptide (MOP) receptors. The prototypical μ-opioid receptor agonist is morphine, the primary psychoactive alkaloid in opium and for which the receptor was named, with mu being the first letter of Morpheus, the compound's namesake in the original Greek. It is an inhibitory G-protein coupled receptor that activates the G_i alpha subunit, inhibiting adenylate cyclase activity, lowering cAMP levels.